source
- Lyora Therapeutics launches to revive early-stage genetic eye disease programs from Editas and BiogenLyora Therapeutics announced its formation as a new genetic‑medicine company focused on eye diseases. The firm will take over several early‑stage programs that were previously in the pipelines of E…
- Former Akero executives launch Avere Therapeutics, unveiling China-sourced pipeline drug and reverse merger planThe former leadership team of Akero Therapeutics announced the creation of a new in‑licensing company called Avere Therapeutics. The launch was made public on Tuesday and includes a pipeline drug…